1. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
- Author
-
Thomas Valerius, Paul W. H. I. Parren, Janine Schuurman, Joost J. Neijssen, William R. Strohl, Kristen M. Chevalier, Luus Wiegman, Cardoso Rosa Maria Fernandes, Mark L. Chiu, Sheri Moores, and G. Mark Anderson
- Subjects
0301 basic medicine ,TGF alpha ,Lung Neoplasms ,Sema domain ,non-small cell lung cancer (NSCLC) ,Apoptosis ,cFAE, controlled Fab-arm exchange ,TKI, tyrosine kinase inhibitor ,Biochemistry ,Epitope ,Tyrosine-kinase inhibitor ,Mice ,amivantamab ,NSCLC, non–small cell lung cancer ,Carcinoma, Non-Small-Cell Lung ,FACS, fluorescence-activated cell sorting ,Antibodies, Bispecific ,Drug Discovery ,Tumor Cells, Cultured ,BsAb, bispecific antibody ,EGFR exon 20 insertion ,Epidermal growth factor receptor ,Antibody-dependent cell-mediated cytotoxicity ,TGI, tumor growth inhibition ,biology ,Chemistry ,bispecific anti-EGFR×MET antibody ,Proto-Oncogene Proteins c-met ,ErbB Receptors ,combinatorial screening ,Female ,MET amplification ,Research Article ,crystal structure ,medicine.drug_class ,Monoclonal antibody ,03 medical and health sciences ,PDB, Protein Data Bank ,non–small cell lung cancer (NSCLC) ,medicine ,Animals ,Humans ,TGFα, transforming growth factor alpha ,mAb, monoclonal antibody ,Molecular Biology ,Cell Proliferation ,ADCC, antibody-dependent cellular cytotoxicity ,030102 biochemistry & molecular biology ,MET, mesenchymal–epithelial transition factor ,Cell Biology ,medicine.disease ,Xenograft Model Antitumor Assays ,EGFR, epidermal growth factor receptor ,epitope mapping ,030104 developmental biology ,Cancer research ,biology.protein ,HGF, hepatocyte growth factor - Abstract
A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients with nonsmall cell lung cancer. In this study, we sequentially screened a panel of BsAbs in a combinatorial approach to select the optimal bispecific molecule. The BsAbs were derived from different EGFR and MET parental monoclonal antibodies. Initially, molecules were screened for EGFR and MET binding on tumor cell lines and lack of agonistic activity toward MET. Hits were identified and further screened based on their potential to induce untoward cell proliferation and crossphosphorylation of EGFR by MET via receptor colocalization in the absence of ligand. After the final step, we selected the EGFR and MET arms for the lead BsAb and added low fucose Fc engineering to generate amivantamab (JNJ-61186372). The crystal structure of the anti-MET Fab of amivantamab bound to MET was solved, and the interaction between the two molecules in atomic details was elucidated. Amivantamab antagonized the hepatocyte growth factor (HGF)-induced signaling by binding to MET Sema domain and thereby blocking HGF beta-chain-Sema engagement. The amivantamab EGFR epitope was mapped to EGFR domain III and residues K443, K465, I467, and S468. Furthermore, amivantamab showed superior antitumor activity over small molecule EGFR and MET inhibitors in the HCC827-HGF in vivo model. Based on its unique mode of action, amivantamab may provide benefit to patients with malignancies associated with aberrant EGFR and MET signaling.
- Published
- 2021